Literature DB >> 26651504

Higher Estradiol and Lower Dehydroepiandrosterone-Sulfate Levels Are Associated with Pulmonary Arterial Hypertension in Men.

Corey E Ventetuolo1,2,3, Grayson L Baird3, R Graham Barr4, David A Bluemke5, Jason S Fritz6, Nicholas S Hill7, James R Klinger1,3, Joao A C Lima8, Pamela Ouyang8, Harold I Palevsky6, Amy J Palmisciano3, Ipsita Krishnan3, Diane Pinder6, Ioana R Preston7, Kari E Roberts7, Steven M Kawut6,9,10.   

Abstract

RATIONALE: Recent studies have focused on the role of female sex and estradiol (E2) in pulmonary arterial hypertension (PAH), but it is not known whether sex hormones are risk factors for PAH in men.
OBJECTIVES: We performed a case-control study to determine whether hormone levels (E2, dehydroepiandrosterone-sulfate [DHEA-S], and testosterone) are associated with PAH in men.
METHODS: Plasma sex hormone levels in men with idiopathic, heritable, or connective tissue disease-associated PAH were compared with those from age- and body mass index-matched men without clinical cardiovascular disease.
MEASUREMENTS AND MAIN RESULTS: There were 23 cases with PAH (70% had idiopathic PAH, 65% were functional class III/IV) and 67 control subjects. Higher E2 and E2/testosterone levels were associated with the risk of PAH (odds ratio per 1 ln[E2:testosterone], 6.0; 95% confidence interval, 2.2-16.4; P = 0.001), whereas higher levels of DHEA-S were associated with a reduced risk (odds ratio per 1 ln[DHEA-S], 0.1; 95% confidence interval, 0.0-0.3; P = 0.001). E2 and DHEA-S levels were strong predictors of case status (C statistic for both, 0.82) but testosterone was not (C statistic, 0.53). Higher levels of E2 were associated with shorter 6-minute-walk distances (P = 0.03), whereas higher levels of DHEA-S were associated with lower right atrial pressure (P = 0.02) and pulmonary vascular resistance (P = 0.01) in men with PAH.
CONCLUSIONS: Higher levels of E2 and lower levels of DHEA-S were associated with PAH in men. Sex-based differences in sex hormone processing and signaling may contribute to unique phenotypes in pulmonary vascular disease.

Entities:  

Keywords:  DHEA; estradiol; pulmonary hypertension; sex hormones

Mesh:

Substances:

Year:  2016        PMID: 26651504      PMCID: PMC4872665          DOI: 10.1164/rccm.201509-1785OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  47 in total

1.  Sex-dependent influence of endogenous estrogen in pulmonary hypertension.

Authors:  Kirsty M Mair; Audrey F Wright; Nicholas Duggan; David J Rowlands; Martin J Hussey; Sonia Roberts; Josephine Fullerton; Margaret Nilsen; Lynn Loughlin; Matthew Thomas; Margaret R MacLean
Journal:  Am J Respir Crit Care Med       Date:  2014-08-15       Impact factor: 21.405

Review 2.  Definitions and diagnosis of pulmonary hypertension.

Authors:  Marius M Hoeper; Harm Jan Bogaard; Robin Condliffe; Robert Frantz; Dinesh Khanna; Marcin Kurzyna; David Langleben; Alessandra Manes; Toru Satoh; Fernando Torres; Martin R Wilkins; David B Badesch
Journal:  J Am Coll Cardiol       Date:  2013-12-24       Impact factor: 24.094

3.  Testosterone replacement effectively inhibits the development of experimental autoimmune orchitis in rats: evidence for a direct role of testosterone on regulatory T cell expansion.

Authors:  Monika Fijak; Eva Schneider; Jörg Klug; Sudhanshu Bhushan; Holger Hackstein; Gerhard Schuler; Malgorzata Wygrecka; Jörg Gromoll; Andreas Meinhardt
Journal:  J Immunol       Date:  2011-03-25       Impact factor: 5.422

4.  Endogenous sex hormones and cardiovascular disease incidence in men.

Authors:  Johan Arnlöv; Michael J Pencina; Shreyasee Amin; Byung-Ho Nam; Emelia J Benjamin; Joanne M Murabito; Thomas J Wang; Philip E Knapp; Ralph B D'Agostino; Shalendar Bhasin; Ramachandran S Vasan
Journal:  Ann Intern Med       Date:  2006-08-01       Impact factor: 25.391

5.  Sex hormone-binding globulin and serum testosterone are inversely associated with C-reactive protein levels in postmenopausal women at high risk for cardiovascular disease.

Authors:  Hylton V Joffe; Paul M Ridker; Joann E Manson; Nancy R Cook; Julie E Buring; Kathryn M Rexrode
Journal:  Ann Epidemiol       Date:  2005-10-10       Impact factor: 3.797

6.  Cardiovascular function in multi-ethnic study of atherosclerosis: normal values by age, sex, and ethnicity.

Authors:  Shunsuke Natori; Shenghan Lai; J Paul Finn; Antoinette S Gomes; W Gregory Hundley; Michael Jerosch-Herold; Gregory Pearson; Shantanu Sinha; Andrew Arai; Joao A C Lima; David A Bluemke
Journal:  AJR Am J Roentgenol       Date:  2006-06       Impact factor: 3.959

7.  Dehydroepiandrosterone activates endothelial cell nitric-oxide synthase by a specific plasma membrane receptor coupled to Galpha(i2,3).

Authors:  Dongmin Liu; Joseph S Dillon
Journal:  J Biol Chem       Date:  2002-04-04       Impact factor: 5.157

8.  Estrogen alters thresholds for B cell apoptosis and activation.

Authors:  Christine M Grimaldi; James Cleary; A Selma Dagtas; Dariush Moussai; Betty Diamond
Journal:  J Clin Invest       Date:  2002-06       Impact factor: 14.808

9.  Activity of the estrogen-metabolizing enzyme cytochrome P450 1B1 influences the development of pulmonary arterial hypertension.

Authors:  Kevin White; Anne Katrine Johansen; Margaret Nilsen; Loredana Ciuclan; Emma Wallace; Leigh Paton; Annabel Campbell; Ian Morecroft; Lynn Loughlin; John D McClure; Matthew Thomas; Kirsty M Mair; Margaret R MacLean
Journal:  Circulation       Date:  2012-08-02       Impact factor: 29.690

10.  Testosterone negatively regulates right ventricular load stress responses in mice.

Authors:  Anna R Hemnes; Karen B Maynard; Hunter C Champion; Linda Gleaves; Niki Penner; James West; John H Newman
Journal:  Pulm Circ       Date:  2012-07       Impact factor: 3.017

View more
  53 in total

Review 1.  The right ventricle and pulmonary hypertension.

Authors:  Mariëlle C van de Veerdonk; Harm J Bogaard; Norbert F Voelkel
Journal:  Heart Fail Rev       Date:  2016-05       Impact factor: 4.214

Review 2.  New and Emerging Therapies for Pulmonary Arterial Hypertension.

Authors:  Edda Spiekerkoetter; Steven M Kawut; Vinicio A de Jesus Perez
Journal:  Annu Rev Med       Date:  2018-09-14       Impact factor: 13.739

3.  Chemokine signaling axis between endothelial and myeloid cells regulates development of pulmonary hypertension associated with pulmonary fibrosis and hypoxia.

Authors:  Aline C Oliveira; Chunhua Fu; Yuanqing Lu; Mason A Williams; Liya Pi; Mark L Brantly; Corey E Ventetuolo; Mohan K Raizada; Borna Mehrad; Edward W Scott; Andrew J Bryant
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2019-07-31       Impact factor: 5.464

4.  Fulvestrant for the Treatment of Pulmonary Arterial Hypertension.

Authors:  Steven M Kawut; Diane Pinder; Nadine Al-Naamani; Amber McCormick; Harold I Palevsky; Jason Fritz; K Akaya Smith; Jeremy A Mazurek; Margaret F Doyle; Margaret R MacLean; Angela DeMichele; David A Mankoff
Journal:  Ann Am Thorac Soc       Date:  2019-11

5.  Back to the Future: Building Up the Case for Exploring Red Blood Cell Morphology in Pulmonary Arterial Hypertension.

Authors:  Bradley A Maron
Journal:  Ann Am Thorac Soc       Date:  2019-05

6.  Inhibiting oestrogen signalling in pulmonary arterial hypertension: sex, drugs and research.

Authors:  Tim Lahm; Steven M Kawut
Journal:  Eur Respir J       Date:  2017-08-03       Impact factor: 16.671

Review 7.  Translational Advances in the Field of Pulmonary Hypertension. Focusing on Developmental Origins and Disease Inception for the Prevention of Pulmonary Hypertension.

Authors:  Bradley A Maron; Steven H Abman
Journal:  Am J Respir Crit Care Med       Date:  2017-02-01       Impact factor: 21.405

Review 8.  Sex, Gender, and Sex Hormones in Pulmonary Hypertension and Right Ventricular Failure.

Authors:  James Hester; Corey Ventetuolo; Tim Lahm
Journal:  Compr Physiol       Date:  2019-12-18       Impact factor: 9.090

Review 9.  Steps forward in the treatment of pulmonary arterial hypertension: latest developments and clinical opportunities.

Authors:  Jessica B Badlam; Todd M Bull
Journal:  Ther Adv Chronic Dis       Date:  2017-03-01       Impact factor: 5.091

Review 10.  Update in Pulmonary Vascular Disease 2015.

Authors:  Bradley A Maron; Mark T Gladwin; Marc A Simon
Journal:  Am J Respir Crit Care Med       Date:  2016-06-15       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.